Safety profile of IBD: lymphoma risks

Gastroenterology Clinics of North America
Meenakshi Bewtra, James D Lewis

Abstract

This article describes the cancer risks of commonly used inflammatory bowel disease (IBD) medications, with an emphasis on hematologic malignancy risks. The increasing use of immunosuppressant therapies in the treatment of IBD has raised this question to an even greater importance. Studies evaluating these medications are complicated due to varying disease severity and concomitant use of other immunosuppressant medication. The potential risks of all therapies must be weighed against the benefits these therapies can offer these patients.

References

Jan 1, 1978·Journal of Chronic Diseases·H A IsomäkiU Joutsenlahti
Jun 1, 1992·Clinical Immunology and Immunopathology·V Santana, N R Rose
Apr 1, 1991·Cancer·A EkbomH O Adami
Oct 1, 1989·Journal of Autoimmunity·I T Cockburn, P Krupp
Oct 15, 1989·Annals of Internal Medicine·D H PresentB I Korelitz
Jan 21, 1985·The American Journal of Medicine·P Prior
Jan 21, 1985·The American Journal of Medicine·T HakulinenP Knekt
Dec 15, 1985·Cancer·A J GreensteinA H Aufses
Feb 17, 1993·Journal of the National Cancer Institute·G GridleyJ F Fraumeni
Aug 26, 1998·Journal of Gastroenterology and Hepatology·F TamuraK Okita
Feb 26, 2000·The Journal of Investigative Dermatology·A Hannuksela-SvahnJ Karvonen
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Jul 23, 2002·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·S ArdizzoneG Bianchi Porro
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·A G FraserD P Jewell
Jan 25, 2003·The Journal of Investigative Dermatology·Carle F PaulLouis Dubertret
Apr 8, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sam M MbulaiteyeEric A Engels
Jun 11, 2003·Chest·Celso T EbeoJay B Mehta
Oct 12, 2004·Inflammatory Bowel Diseases·Alessandra LoscoGuido Basilisco
Dec 31, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Karen V WintherVibeke Binder
Feb 9, 2005·Journal of Pediatric Gastroenterology and Nutrition·Meena ThayuRobert N Baldassano
Sep 7, 2005·Gastroenterology·Stefan SchreiberUNKNOWN CDP870 Crohn's Disease Study Group
Sep 9, 2005·European Journal of Gastroenterology & Hepatology·Derek P JewellScot Buchan
Oct 28, 2005·Transplantation·Joseph F BuellE Steve Woodle
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Feb 8, 2006·Journal of Gastroenterology and Hepatology·Takeshi ShibaharaNaomi Tanaka
Jul 21, 2006·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Lauren K SchwartzEllen Scherl
Nov 9, 2006·JAMA : the Journal of the American Medical Association·Eric L Matteson, Tim Bongartz

❮ Previous
Next ❯

Citations

May 25, 2012·The British Journal of Nutrition·Eduard CabréMiquel A Gassull
Mar 24, 2012·Journal of Crohn's & Colitis·Ashwin N Ananthakrishnan, Emily L McGinley
Jan 26, 2016·Alimentary Pharmacology & Therapeutics·P VedakA N Ananthakrishnan
Aug 30, 2013·Expert Review of Gastroenterology & Hepatology·Ashwin N Ananthakrishnan
Feb 6, 2010·Nature Reviews. Gastroenterology & Hepatology·Geert R D'Haens
Apr 14, 2015·Alimentary Pharmacology & Therapeutics·A N AnanthakrishnanK P Liao
Jul 6, 2012·The American Journal of Gastroenterology·Meenakshi Bewtra
May 5, 2017·Alimentary Pharmacology & Therapeutics·A N AnanthakrishnanR S Sandler

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.